Mepolizumab Beneficial in COPD With Eosinophilic Phenotype
Lower annual rate of moderate, severe exacerbations for patients receiving 100 mg mepolizumab
Conclusions LAMA or ICS/LABA combinations use was associated with a lower risk of acute exacerbation in patients with COPD and asthma in this study.
(MedPage Today) -- Patients could benefit from regular monitoring for BMD, fracture risk
This article is protected by copyright. All rights reserved.
Short-acting β2 agonists (SABA) are administered primarily using pressurized metered-dose inhalers (pMDIs). Albuterol multidose dry powder inhaler (MDPI; ProAir RespiClick®), a novel, breath-actuated device, eliminates hand-breath coordination required of pMDIs. A gap exists in understanding real-world differe nces in patients prior to receiving albuterol MDPI or SABA pMDI.
Many contributing factors have been implicated in allergic asthma exacerbations, including infection, pollution, ozone, and increasingly, chronic lung disorders such as cystic fibrosis (CF) and chronic obstructive pulmonary disorder (COPD). A method of allergen desensitization effective in these vulnerable and often immunocompromised populations is urgently needed for public health reduction of complications and deaths from allergic asthma.
Elevated PAI-1 levels are associated with worse outcomes in COPD. It is unknown whether elevated PAI-1 affects lung function, or risk of COPD / emphysema in healthy adults.
To find useful biomarkers for a differential diagnosis between asthma and COPD, we evaluated NAGL (neutrophil gelatinase-associated lipocalin), sRAGE (soluble receptor for advanced glycosylation end products), and anti-elastin antibody.
Endothelial dysfunction and change in vascular permeability are key events in many allergic diseases including edema and chronic obstructive pulmonary disease (COPD). On the molecular level, mitochondrial dysfunction contributes to the elevation of reactive oxygen species (ROS), which can then destabilize mitochondrial membrane potential. Now, research demonstrates that aldehyde dehydrogenase 2 (ALDH2) could be an invaluable combatant against mitochondrial dysfunction. Human carriers possessing an inactive ALDH2 variant have been found to be more susceptible to COPD and asthma.
It is not known how early lung function deficits occurs in smokers and when it shows signs of lack of reversibility, which would indicate risk of developing COPD.
We report the effect of EDS-FLU on QoL as measured by the Rhinosinusitis Disability Index (RSDI).